MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2015/06/30
Phase 4
Completed
Recep Tayyip Erdogan University
2015/06/08
Phase 3
Completed
IRCCS Burlo Garofolo
2015/05/21
Phase 2
UNKNOWN
2015/05/15
Phase 4
Completed
2015/05/12
Not Applicable
Completed
2015/05/12
Phase 2
UNKNOWN
Lagos State Health Service Commission
2015/05/07
Phase 4
Completed
2015/04/29
Phase 3
UNKNOWN
2015/04/24
Phase 3
UNKNOWN
2015/04/17
Phase 3
UNKNOWN

FDA Approved Products

View More FDA Products

Sign in to access additional FDA-approved products with detailed regulatory information.

Product Name
Manufacturer
Route
Strength
Approved
NDC Code
ORAL
200 mg in 1 1
2023/02/15
76420-537
ORAL
100 mg in 1 1
2011/09/22
68258-2003
ORAL
100 mg in 1 1
2010/11/19
16590-253
ORAL
37.5 mg in 1 1
2012/08/29
54868-4703
ORAL
300 mg in 1 1
2010/11/19
16590-255
ORAL
200 mg in 1 1
2023/06/13
50090-5106
ORAL
50 mg in 1 1
2010/04/09
63874-532
ORAL
100 mg in 1 1
2021/06/30
71335-1675
ORAL
200 mg in 1 1
2022/12/28
63629-8319
ORAL
37.5 mg in 1 1
2023/10/02
68788-7855

EMA Approved Products

View More EMA Products

Sign in to access additional EMA-approved products with authorization details.

Medicine Name
EMA Number
Auth. Holder
Country
Drug Type
Status
Issued
Opinion
Revision

No EMA products found

No EMA products found for this drug

HSA Approved Products

View More HSA Products

Sign in to access additional HSA-approved products with regulatory information.

Product Name
Manufacturer
Dosage Form
Strength
Approved
Approval No.

No HSA products found

No HSA products found for this drug

NMPA Approved Products

View More NMPA Products

Sign in to access additional NMPA-approved products with approval information.

Product Name
Approval No.
Manufacturer
Dosage Form
Trade Name
Strength
Type
Status
Date
Import

No NMPA products found

No NMPA products found for this drug

PPB Approved Products

Product Name
Registration Code
Company
Category
Sale Type
Reg. Date
HK-68607
Part 1, Schedule 1 & Schedule 3 Poison
POM
2025/03/12
HK-68684
Part 1, Schedule 1 & Schedule 3 Poison
POM
2025/05/12
HK-41704
Part 1, Schedule 1 & Schedule 3 Poison
POM
1997/01/14
HK-45325
Part 1, Schedule 1 & Schedule 3 Poison
POM
1999/09/15
HK-38308
jean-marie pharmacal co ltd
Part 1, Schedule 1 & Schedule 3 Poison
POM
1994/12/07
HK-66984
Part 1, Schedule 1 & Schedule 3 Poison
POM
2021/02/17

TGA Approved Products

View More TGA Products

Sign in to access additional TGA-approved products with licensing information.

Product Name
ARTG ID
Sponsor
Status
Reg. Date
Ingredient

No TGA products found

No TGA products found for this drug

© Copyright 2025. All Rights Reserved by MedPath